Form 4: Longeveron CMO Nataliya Agafonova Receives RSU Grant

Longeveron Inc. Chief Medical Officer Nataliya Agafonova was granted 250,000 restricted stock units as part of an equity incentive.

Summary

• Chief Medical Officer Nataliya Agafonova acquired 250,000 shares of Class A Common Stock via a Restricted Stock Unit (RSU) award.
• The transaction occurred on May 1, 2026.
• Following this transaction, the reporting person holds a total of 453,419 shares of Class A Common Stock.
• The RSU award is subject to time-based vesting conditions.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding executive compensation with no immediate impact on company operations or financial health.

Positives

• Alignment of executive interests with long-term shareholder value through equity-based compensation.

Negatives

• Potential for future shareholder dilution upon the vesting and settlement of the RSU awards.

Risks

• Vesting of equity awards is subject to continued employment and performance conditions.
• Market volatility may impact the future value of the granted equity.

Future Outlook

The filing does not provide specific forward-looking financial guidance, focusing solely on the disclosure of executive equity compensation.

Industry Context

StockSavvy.ai notes that equity grants to C-suite executives in the biotechnology sector are standard practice for retention and performance alignment, particularly in clinical-stage companies.

Comparison to Industry Standards

• The grant of time-based RSUs is consistent with standard executive compensation packages for publicly traded small-cap biotech firms.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual vesting and issuance of the underlying shares.

Next Steps

• Vesting of the granted restricted stock units according to the company's internal schedule.

Key Dates

Keywords

Longeveron, LGVN, Insider Trading, Form 4, Equity Compensation, Biotech